SIOUX FALLS, S.D.—Balance Ophthalmics, a medical device company advancing non-pharmacological, non-surgical treatment options for glaucoma, has announced the appointment of Norbert Lowe as chief commercial officer, effective immediately. In this new role, Lowe will lead the company’s commercial strategy and execution as it prepares to expand awareness and adoption of the FSYX (pronounced “physics”) Ocular Pressure Adjusting Pump (OPAP). Balance said this appointment comes at a pivotal time, following the FDA 510(k) clearance of the wireless-enabled next-generation FSYX system in May 2026 and ahead of anticipated broader commercialization.